|Articles|December 1, 1996

Pharmacoeconomic and Healthcare Outcomes Research: Managing and Treating Hypertension and Cardiovas
Volume 2
Issue 12 Suppl

Felodipine as an Alternative to More Expensive Calcium Antagonists in Mild to Moderate Hypertension

Author(s)Major Frank J. Landry, MD, MPH, Captain J. David Horwhat, MD, David Tomich, PharmD

Download PDF: Felodipine as an Alternative to More Expensive Calcium Antagonists in Mild to Moderate Hypertension

Articles in this issue

over 29 years ago

Article

Introduction

over 29 years ago

Article

Process and Outcome of Outpatient Management of Heart Failure: A Comparison of Cardiologists and Primary Care Providers

over 29 years ago

Article

Gatekeepers and Managed Care: Too Much of a Good Thing?

over 29 years ago

Article

Clinical Outcome of a Mandatory Formulary Switch for Dihydropyridine Calcium Channel Blocker Therapy at a Veteran's Administration Medical Center

over 29 years ago

Article

An Analysis of Costs and Complications of Monophasic and Biphasic Implantable Cardioverter Defibrillators

over 29 years ago

Article

Determinants of Hospital Charges and Costs in Acute Myocardial Infarction: A Report from the Myocardial Infarction Cost Study (MICS) Group

over 29 years ago

Article

Aspirin after Myocardial Infarction: Patient Experience in a Managed Care Setting

over 29 years ago

Article

MANAGED CARE CLINICAL CORNER: Chest Pain

over 29 years ago

Article

Selected Abstracts

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Felodipine as an Alternative to More Expensive Calcium Antagonists in Mild to Moderate Hypertension

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care